MetaCap

Aktis Oncology (AKTS) vs Mentari Therapeutics (MTRI)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Aktis Oncology is the larger company by market cap ($901.1 million vs $856.9 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AKTS-34.67%MTRI+0.68%
+40%-2%-45%
Aug 17, 20261 yearNov 20, 2026
AKTS-32.90%MTRI+0.68%
+31%-5%-41%
Aug 17, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AKTS versus MTRI key metrics
MetricAKTSMTRI
Share price$16.15$14.70
Market cap$901.14M$856.94M
1-day change-1.52%-3.57%
EPS (TTM)$-1.80—
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
52-week high$34.19$23.30
52-week low$13.96$5.75
Distance from 52-week high-52.76%-36.91%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+122.17%—
Average volume408.46K19.42K
Shares outstanding53.93M58.30M
Employees79—
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Aktis Oncology

AKTS stock →

Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 79 employees

About Mentari Therapeutics

MTRI stock →

Mentari Therapeutics, Inc., a biotechnology company, develops and provides therapies for migraine prevention. The company's products include MT-001, an anti-PACAP monoclonal antibody designed for convenient subcutaneous dosing; MT-002, an anti-CGRP; and anti-PACAP bispecific antibody designed to inhibit these complementary pathways.

Health Care · Biotechnology: Pharmaceutical Preparations

AKTS vs MTRI FAQ

Which is bigger, Aktis Oncology or Mentari Therapeutics?

Aktis Oncology (AKTS) is larger, with a market capitalization of $901.14M compared with $856.94M for Mentari Therapeutics (MTRI).

Are Aktis Oncology and Mentari Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons